AXON logo

Axon Enterprise

AXON · What the business does, what can go wrong, and how options sellers approach it

What it does

Axon Enterprise builds technology for law enforcement, corrections, and other public safety agencies. It is best known for the TASER brand of conducted energy devices and for body-worn cameras. It also sells in-car and fixed cameras, drones and related security technology, training tools, and cloud software for storing and managing digital evidence.

The company's pitch is that these pieces work together, so a camera recording flows into cloud software that agencies use to organize, review, and share evidence.

How it makes money

Axon reports two segments: Connected Devices and Software and Services.

Connected Devices covers hardware sales, including TASER devices, cameras, and accessories. Software and Services covers cloud subscriptions and related services, often sold alongside the hardware under multi-year contracts. Subscription-style revenue tends to recur, while hardware sales can be lumpier and depend on agency purchasing cycles.

Why investors own it

Investors often view Axon as a way to own a specialized public safety technology business, with a well-known brand and long-standing relationships with public safety agencies. Once an agency stores its evidence in a vendor's system and trains staff on it, switching can be disruptive, which may support customer retention.

Some also like the shift toward recurring software revenue, which can make results more predictable than hardware alone.

What can go wrong

  • Government budgets and procurement schedules can delay or shrink orders.
  • Product liability claims, regulatory scrutiny, and public debate over use-of-force tools can create legal and reputational costs.
  • Competitors in cameras and evidence software may pressure pricing.
  • Newer areas such as drones and AI-assisted tools bring execution and policy risks.
  • A growth-oriented stock can fall sharply if results or guidance disappoint.

What to watch

  • Annual recurring revenue
  • Connected Devices revenue and TASER product cycles
  • Contract bookings and backlog
  • Changes in public safety budgets and regulation

Options income angle

Near-term AXON options tend to be reasonably liquid, though spreads can widen in far-dated or far out-of-the-money strikes.

Implied volatility tends to rise before quarterly earnings and around contract, product, legal, or policy news.

One caution for premium sellers: the stock can gap sharply after earnings, so a covered call can cap gains in a rally and a cash-secured put can leave you owning shares after a steep drop.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 25, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Axon reported 2025 revenue of $2.8 billion, an increase of $697.0 million, or 33.5%, but swung to a loss from operations of $62.1 million. Stock-based pay and hiring grew faster than sales. The filing also says a material weakness (a flaw in financial-reporting controls) tied to revenue recognition was not yet fixed as of December 31, 2025, and the company took on $1.75 billion of Senior Notes.

How the business did

  • Both segments grew. Software and Services rose 39.6%, driven by more users and premium add-on features. Connected Devices rose 29.1%, with Platform Solutions up 72.5% on counter-drone equipment, virtual reality training and fleet systems. TASER grew 21.8%.
  • Operating expenses rose by $537.4 million on headcount and stock-based compensation. R&D expense rose 55.0%. Management also recorded non-recurring severance costs of $28.7 million in SG&A in the fourth quarter.
  • Net income fell to $124.7 million from $377.0 million. It included gains of $186.4 million on strategic investments and a $105.7 million tax benefit, offset by a $46.4 million loss on marketable securities and $38.9 million of inducement expense for the early repurchase of part of the 2027 Notes.
  • Adjusted gross margin, which strips out items such as stock-based pay, fell to 62.6% from 63.2%, mainly because of global tariffs and a higher mix of Platform Solutions revenue.
  • Operating cash flow was $211.3 million, down from $408.3 million. Receivables and contract assets absorbed cash as sales grew. Financing brought in gross proceeds of $1.8 billion from the Senior Notes and net proceeds of $489.6 million from an at-the-market program, in which the company sells new shares over time.

Risks specific to this company

  • Control weaknesses and restatements: The material weakness on revenue recognition remains open. The company also revised earlier statements over principal-versus-agent accounting and restated for how the 2027 Notes were classified, which the filing says could invite litigation or regulatory action.
  • Reliance on law enforcement and TASER: U.S. law enforcement is the largest customer vertical, and CEDs (conducted energy devices, the TASER line) account for a significant portion of revenue. The filing says negative publicity has hurt sales in the past.
  • Regulation of the TASER 10: The ATF regulates it as a firearm and could limit, fine or suspend the product line. Import permits restrict sourcing, and raw materials come from a limited number of suppliers that are hard to replace.
  • Government budgets and contracts: Many customers are agencies that can cancel contracts for convenience or fail to appropriate funds. The filing cites the 2025 federal shutdown as an example of these disruptions.
  • Product liability litigation: The company says it is subject to a number of lawsuits over injuries and deaths linked to its products. Damages could exceed insurance, and insurers may decline coverage.
  • Debt and tariffs: The revolving credit facility and the notes carry restrictive covenants. Tariffs, especially involving the PRC, Mexico and Canada, are already raising supply costs.

What management is watching

  • Management points investors to non-GAAP measures: EBITDA, adjusted EBITDA and adjusted gross margin. It says they exclude items it does not consider core, and they are not a substitute for GAAP results.
  • After year-end, the company acquired Carbyne, an emergency communications platform, for a base purchase price of $625.0 million, paid from cash on hand. It also settled the remaining 2027 Notes in February 2026, so none remain outstanding.
  • The company is stocking up to support future sales, with advanced raw material purchases for Axon Body 4 and TASER 10 CEDs. It also notes supplier prepayments as bookings continue to grow.
  • On liquidity, the company had $1.2 billion of cash and cash equivalents and a $300.0 million revolving credit facility with no amounts drawn. Management believes funding is sufficient for at least the next 12 months and says it expects to remain an opportunistic issuer of debt.
  • Stock-based compensation, including the Employee XSP and CEO Performance Award programs, remains a major cost driver. Management describes headcount growth as supporting business growth.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Axon's revenue for the three months ended September 30, 2026 was $908.6 million, up 27.8% from a year earlier, and the company reported income from operations of $42.1 million versus a loss of $2.1 million. Growth came with lower margins, mainly from counter-drone equipment, new products and memory costs. Net income of $57.0 million leaned heavily on gains from strategic investments, and the company added debt-related risk language.

How the business did

  • Quarter: Gross margin fell to 56.7% of revenue from 60.1%. Adjusted gross margin, which strips out items like stock compensation and acquisition-related amortization, fell to 59.2% from 62.7%. Net income included income from strategic investments, net, of $64.1 million and a $21.9 million tax provision.
  • Segments: Software and Services grew 43.2%, driven by more users and wider adoption of premium solutions. In Connected Devices (hardware), Platform Solutions rose $64.2 million on counter-drone equipment, Personal Sensors rose $6.9 million on the AB4 body camera, and TASER fell $4.9 million on lower legacy TASER volume.
  • Nine months: Revenue was $2.6 billion, up 32.2%. Income from operations was $118.1 million versus a loss of $12.0 million. Net income was $255.7 million, including $266.4 million of net gains on strategic investments. Management also noted $47.4 million of tariff refunds received in the second quarter.
  • Cash and capital: Operating cash flow for the nine months was $8.2 million. Cash and cash equivalents were $1.5 billion. The company spent $552.0 million on business combinations, substantially all for Carbyne. It raised $1.15 billion from the 2031 Notes and $100.3 million from its at-the-market stock program.

What management is watching

  • Operating expenses rose $43.4 million in the quarter, which management attributed to headcount and investments in AI and other initiatives. Technology license costs for AI adoption were a named driver.
  • The filing says counter-drone sales may be volatile because of the timing of large customer contracts. It gives no numerical outlook for the rest of the year.
  • On November 5, 2026, the company agreed to make incremental minority investments of up to $1.2 billion in Skydio. It expects up to approximately $720.0 million in cash, with the rest in company stock. It paid approximately $127.5 million in cash at closing of the primary investment.
  • Management points to adjusted EBITDA and adjusted gross margin. It changed how both are calculated during 2026 and did not restate prior periods.

New or changed risks

  • Leftover hedges: Part of the 2027 Note Hedge and 2027 Warrant transactions remains outstanding even though the 2027 Notes are gone. The warrants could dilute shareholders if the stock price exceeds their strike price.
  • 2031 Capped Calls: Entered in September 2026, these may reduce dilution from the 2031 Notes, but only up to a cap. The banks on the other side may trade the stock to adjust their positions, which could move the price. The company also faces unsecured counterparty risk if one of those banks defaults.
  • Covenants: The revolving credit facility, amended in September 2026, and the note indentures restrict additional debt, asset sales and mergers. The revolver also requires specified financial ratios.
  • 2031 Notes conversion: Conversion could require cash or issue shares, hurting liquidity or diluting holders. The company may also need cash for repurchases or refinancing, possibly on unfavorable terms.

Follow AXON in Kortex

The Kortex app shows AXON's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.